Cardiovascular diseases in Belgium: sugar, platelets, TXA2 and ginger (2025)

Belgian Cardiovascular Epidemiology

• ~30% of deaths in Belgium = CVD (Sciensano 2024)
• ~700 new heart attacks per week in Belgium
• Direct medical costs of CVD: ~3 billion €/year
• Average Belgian sugar consumption: 95g/day (2× WHO recommendation)

Molecular Mechanisms: Sugar and Vascular Pathology

1. TXA2 and Platelet Activation

Thromboxane A2 (TXA2) is the key mediator of platelet aggregation:

• Hyperglycemia → platelet PKC activation → TXA2 ↑
• TXA2 → TP receptors on platelets → aggregation amplification → thromboembolic risk
• TXA2 → vasoconstriction → coronary/cerebral ischemia
• Fructose → uric acid → xanthine oxidase → ROS → TXA2 ↑ (indirect mechanism)
• GIMBER (~35g sugar/100ml) × 3 intakes/day = high glycemic load → chronically elevated TXA2

2. Endothelial NF-κB and Atherosclerosis

• AGE → RAGE → NF-κB in endothelial cells → ICAM-1, VCAM-1, E-selectin
• Monocytes → endothelial adhesion → transmigration → intimal macrophages
• Macrophages → foam cells (oxidized cholesterol-ldl-reduire-naturellement">LDL phagocytosed) → lipid streaks → atherosclerotic plaque
• NF-κB → MMP-9 → fibrous cap destabilization → vulnerable plaque → ACS (acute coronary syndrome)

3. eNOS and Endothelial Dysfunction

• Hyperglycemia → O-GlcNAc modification of eNOS → activity ↓ → NO ↓
• Fructose → uric acid → eNOS uncoupling → superoxide instead of NO (oxidative paradox)
• NO ↓ → vasoconstriction → HTA → acceleration of atherosclerosis → vicious circle
• NO ↓ → facilitated platelet aggregation (NO normally inhibits platelets)

Ginger and Cardioprotection: Scientific Data

6-Gingerol and Platelets

• 6-gingerol → platelet COX-1 inhibition → TXA2 ↓ → mild antiplatelet
• Ginger → ↑ prostacyclin (PGI2, vasodilating and antiplatelet) → improved TXA2/PGI2 balance
• Clinical study (Verma 2004): 5g ginger/day → ↓ ADP-induced aggregation in healthy subjects

⚠️ Critical Anticoagulant Interactions

• Aspirin/clopidogrel/ticagrelor → increased bleeding risk → mandatory cardiology advice
• Warfarin/acenocoumarol/rivaroxaban/apixaban → anticoagulant potentiation → INR monitoring
• Always inform your cardiologist or treating physician